OncLive TV

Dr. Minna on Chemotherapy and Radiation Therapy for Lung Cancer

November 2nd 2015

John Minna, MD, Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology, Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research, Hamon Center for Therapeutic Oncology, Internal Medicine, Pharmacology, UT Southwestern Medical Center, discusses the roles that both chemotherapy and radiation therapy will continue to have in the treatment of lung cancer.

Dr. Moul on Challenges With Sequencing Therapies for Prostate Cancer

October 30th 2015

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses challenges with sequencing therapies for prostate cancer.

Dr. Yael Cohen on Anti-Angiogenic Agent VB-111

October 29th 2015

Yael Cohen, MD, vice president of Clinical Development at VBL Therapeutics Pharmaceuticals, discusses VB-111, a highly targeted anti-angiogenic agent that is being investigated in several tumor types.

Dr. Vicini on Accelerated Partial Breast Irradiation in Low-Risk Breast Cancer

October 29th 2015

Frank A. Vicini, MD, radiation oncologist, 21st Century Oncology of Michigan, discusses a European study that examined the efficacy of accelerated partial breast irradiation versus conventional whole breast irradiation in patients with low-risk breast cancer.

Dr. Federman on Ongoing Research in Rare Bone and Soft Tissue Sarcoma

October 28th 2015

Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles (UCLA), discusses ongoing research in rare bone and soft tissue sarcoma.

Dr. Kipps on Frontline Therapies in CLL

October 27th 2015

Thomas J. Kipps, MD, PhD, deputy director of Research, Moores University of California, San Diego Cancer Center, professor of Medicine, University of California San Diego, School of Medicine, discusses use of frontline therapies for patients with chronic lymphocytic leukemia.

Dr. Saad on Next Steps for Radium-223 in mCRPC

October 26th 2015

Fred Saad, MD, FRCS, professor, Department of Surgery, University of Montreal, discusses expected next steps associated with radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer.

Dr. Ferrajoli on Treatment of Elderly Patients With CLL

October 22nd 2015

Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses treatment options for elderly patients with chronic lymphocytic leukemia.

Dr. Reidy Lagunes on the Potential of Immunotherapy in NETs

October 21st 2015

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential of immunotherapy agents in the treatment of patients with neuroendocrine carcinoma.

Dr. Shpall on Therapeutic Agents for the Treatment of CLL

October 20th 2015

Elizabeth J. Shpall, MD, professor, deputy department chair, Department of Stem Cell Transplantation, Division of Cancer Medicine, medical director, Cell Therapy Laboratory, director, Cord Blood Bank, the University of Texas MD Anderson Cancer Center, discusses idelalisib and ibrutinib for the treatment of patients with chronic lymphocytic leukemia.

Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell Carcinoma

October 19th 2015

Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a second-line therapy for metastatic renal cell carcinoma.

Dr. Patricia LoRusso on Next-Generation Sequencing Benefit in Metastatic Melanoma Treatment

October 16th 2015

Patricia M. LoRusso, DO, Professor of Medicine and Associate Director of Innovative Medicine, Yale Cancer Center, discusses taking a personalized medicine approach to treat melanoma patients whose tumors do not have BRAF alterations.

Dr. Memarzadeh on Recurrence Rates in Ovarian Cancer

October 13th 2015

Sanaz Memarzadeh, MD, PhD, gynecologic oncology, obstetrics and gynecology, University of California, Los Angeles, discusses recurrence rates in ovarian cancer.

Dr. Raffit Hassan on Avelumab in Unresectable Mesothelioma

October 12th 2015

Raffit Hassan, MD, Co-Chief Thoracic and Gastrointestinal Oncology Branch, Senior Investigator Head, Thoracic and Solid Tumor Immunotherapy Section at the Center for Cancer Research, National Cancer Institute, discusses a recent phase IB trial investigating avelumab in unresectable mesothelioma.

Dr. Kumar on Defining Multiple Myeloma

October 12th 2015

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, gives an overview on the expanded definition of multiple myeloma.

Rebecca Feldman on Oncogenic Role of Caveolin-1 in Breast Cancer

October 9th 2015

Rebecca Feldman, PhD, molecular science liaison/research scientist, Caris Life Sciences, discusses caveolin-1 as potentially having an oncogenic role in breast cancer.

Dr. Maha Hussain on Novel Approaches in Prostate Cancer

October 8th 2015

Dr. Montes on the Relationship of MRI Imaging Characteristics With Race

October 8th 2015

Jennifer Montes, MD, NYU Langone Medical Center, discusses a recent study that examined the relationship of magnetic resonance imaging (MRI) characteristics with race in breast cancer.

Dr. Nazha on Mutational Model to Predict Response to Hypomethylating Agents in MDS

October 7th 2015

Aziz Nazha, MD, hematologist, Leukemia Program at the Cleveland Clinic, Taussig Cancer Institute, discusses results of a mutational model to predict response to hypomethylating agents in myelodysplastic syndromes (MDS).

Dr. Mayer on Toxicities Associated With Therapies for ER+ Breast Cancer

October 6th 2015

Ingrid A. Mayer, MD, associate professor of medicine, co-leader and clinical director, Breast Cancer Research Program, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses toxicities that are associated with therapies for ER-positive metastatic breast cancer.